Almacor

Quick links to important sections

Almacor

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Almacor

Quick Facts

Property Description
Active ingredient Amlodipine (typically as Amlodipine besylate)
Form Oral tablet (long-acting)
Pharmacological class Dihydropyridine Calcium Channel Blocker (CCB)
General Purpose Reducing peripheral vascular resistance
Origin Synthetic organic compound

What Type of Medicine is Almacor?

Almacor is a prescription medication containing the active substance Amlodipine, which is chemically defined as a synthetic organic compound. Its pharmacological class is the Dihydropyridine calcium channel blocker (CCB). This classification places the drug within a group of compounds utilized to modulate the mechanical function of the cardiovascular system.

Amlodipine is distinguished from other CCBs, such as Verapamil or Diltiazem (non-dihydropyridines), by its high selectivity for peripheral blood vessels. This selective action defines its identity as a peripheral arterial vasodilator. Its prolonged therapeutic half-life is a key differentiator, supporting the convenience of once-daily dosing for sustained effect.

Composition, Origin, and Available Form

The active chemical entity in Almacor is Amlodipine, typically formulated as the salt Amlodipine besylate, which is developed through chemical synthesis. The medication is prepared for oral administration, most commonly as a tablet.

Due to its extended duration of action, Amlodipine is categorized as a long-acting agent. While utilized as a single-entity product (monotherapy), Amlodipine is also available as a component in various fixed-dose combination preparations. The tablet form contains the active ingredient alongside standard solid excipients to allow for stable drug delivery.

General Purpose: How it Affects Blood Flow

The general purpose of Almacor is to lower resistance within the circulatory system by regulating the movement of calcium ions (Ca^2+). Specifically, Amlodipine functions as a slow-channel blocker that inhibits the influx of these ions into the smooth muscle cells lining the arteries.

This inhibition causes the vascular muscles to relax, leading to vasodilation—the widening of the arteries. This process relaxes blood vessels, which reduces the effort required by the heart to pump blood. The physiological result of this targeted action is a significant reduction of peripheral vascular resistance, which eases the workload on the heart and supports the sustained maintenance of systemic blood pressure.

Regulatory References

  1. DailyMed - NIH
  2. StatPearls - NCBI
  3. U.S. National Library of Medicine
  4. MedlinePlus Drug Information

What side effects are possible with Almacor?

Almacor (generic name amlodipine) is a calcium channel blocker primarily used to treat high blood pressure (hypertension) and certain types of chest pain (angina).

Common Side Effects

Most patients tolerate Almacor well, but some may experience common side effects, which typically occur at the start of treatment and may decrease over time. These include:

  • Headache
  • Dizziness and sleepiness
  • Flushing or warming of the face and neck
  • Swelling in the ankles or feet (edema)
  • Feeling sick (nausea) or stomach pain
  • Tiredness and weakness

Serious Side Effects and When to Seek Medical Attention

Although rare, some side effects require immediate medical attention. Contact your doctor right away if you experience:

  • Sudden wheezing, chest pain, or difficulty breathing
  • Swelling of the eyelids, face, or lips
  • Severe skin reactions, including intense rash, blistering, or peeling skin
  • Heart attack or an abnormal heartbeat (palpitations)
  • Inflammation of the pancreas, which may cause severe abdominal and back pain

Contraindications and Precautions

Almacor is not recommended for use in all patients. It is contraindicated in people with known hypersensitivity to amlodipine or other dihydropyridine derivatives. Caution is advised for patients with certain pre-existing conditions, particularly severe low blood pressure, severe heart failure, or severe liver problems, as dosage adjustments or closer monitoring may be necessary.

Drug Interactions

This medication may interact with other substances, potentially increasing or decreasing its effects. Key interactions include certain anti-fungal medicines (e.g., ketoconazole), some HIV protease inhibitors (e.g., ritonavir), and the cholesterol-lowering medicine simvastatin. Consuming large quantities of grapefruit or grapefruit juice may also increase the effects of the drug. Always inform your healthcare provider about all prescription drugs, over-the-counter medicines, and herbal supplements you are taking.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Almacor (Amlodipine) overdosage focuses on the risk of severe cardiovascular events resulting from excessive peripheral vasodilation. The primary documented manifestation is marked and prolonged systemic hypotension (severely low blood pressure), which may be accompanied by reflex tachycardia (rapid heart rate) or, less commonly, profound bradycardia (slow heart rate). Overdose may present with clinical signs such as dizziness, lightheadedness, and weakness.

Severe Outcomes and Emergency Action

A significant concern is the potential for the patient’s state to rapidly progress to cardiogenic shock and refractory hypotension. Regulatory authorities classify this as a severe risk, noting that fatal outcomes have been reported. Official labeling mandates that users seek immediate medical attention or emergency medical care immediately upon suspicion of overdosage.

Due to the drug's extended duration of action, hospitalisation and continuous cardiac monitoring are required to manage the potential for delayed or sustained effects.

Official Management Principles

As no specific antidote is known, the management strategy outlined in regulatory documents is purely symptomatic and supportive. Recommended procedural measures may include the use of activated charcoal if administered early to reduce absorption. Treatment focuses on restoring blood pressure and cardiovascular stability through the administration of intravenous fluids and, if necessary, the use of vasopressor agents and intravenous calcium gluconate.

Therapeutic Uses of Almacor

Almacor (Amlodipine) is commonly used to help with high blood pressure, certain conditions involving angina, and coronary artery disease.

This medication is applied across therapeutic domains involving systemic imbalance and heightened physiological activity. It plays a role in managing chronic conditions such as hypertension in adults and certain pediatric patients, as well as the symptomatic burden of chronic stable angina and vasospastic angina (Prinzmetal’s). For patients with documented coronary artery disease, it is considered relevant for long-term supportive benefit.

“Consistent daily use supports the process of mitigating potential long-term strain on vital organs, which may assist in the support of stable blood pressure levels.”

Almacor is commonly used when short-term symptomatic assistance is needed to ease the frequency and intensity of chest pain episodes, which may assist with maintaining functional stability. It plays a role in managing the possibility of major negative outcomes for those with existing heart conditions, offering supportive relief relevant to managing the overall symptom load.


Quick Fact: Relief for Cardiovascular Symptom Burden Property Description
Primary Indication Sustained management of systemic high blood pressure
Symptom Focus Recurrent chest pain (angina pectoris)
Core Benefit Contributes to maintaining stable cardiovascular pressure
Usage Context Supportive management in the context of documented CAD

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Almacor

The eligibility for Almacor (Amlodipine) is strictly determined by governmental regulatory labeling, which defines absolute prohibitions and conditional use requirements across different populations.

Classification Regulatory Status
Populations Allowed Adults (age 18 and older); Pediatric patients (ages 6 to 17 years) for hypertension.
Conditional Use Older adults; Patients with hepatic impairment; Patients with congestive heart failure.
Use Not Established Pediatric patients younger than 6 years old.
Not Recommended Patients who are breastfeeding/lactating.

Absolute Contraindications

Use of Almacor is strictly prohibited in patients with a known hypersensitivity to Amlodipine, other dihydropyridine derivatives, or any formulation excipients. Furthermore, the medicine is contraindicated in specific states of cardiovascular instability, including:

  • Severe hypotension
  • Shock (including cardiogenic shock)
  • Obstruction of the left ventricular outflow tract (e.g., high grade aortic stenosis)
  • Haemodynamically unstable heart failure following acute myocardial infarction

Organ Function and Reproductive Status

  • Hepatic Impairment: Requires caution; patients must be initiated at the lower end of the dosing range, as dosage recommendations are not established for mild-to-moderate impairment.
  • Renal Impairment: Generally does not require a dosage adjustment.
  • Pregnancy: Use is restricted and permitted only when the potential benefit is judged to outweigh the potential risk to the fetus.

What should I know about interactions with other medicines?

Interactions with Other Medicines

The official interaction profile for Amlodipine centers on its metabolism by the Cytochrome P450 (CYP) 3A4 enzyme system. Co-administration with strong or moderate CYP3A4 inhibitors, such as Itraconazole or Clarithromycin, is documented to cause a significant increase in Amlodipine systemic exposure. Conversely, documented CYP3A4 inducers, including Rifampicin and the herbal product St. John's Wort, may lead to a reduction in plasma concentration.

Regulatory Constraints on Co-Administration

Specific restrictions are documented for certain combinations. Co-administration with Simvastatin results in a 77% increase in Simvastatin exposure, leading to a regulatory constraint that formally limits the Simvastatin dose to a maximum of 20 mg daily. The use of Amlodipine with Intravenous Dantrolene is officially cautioned against. Additive blood pressure lowering effects are documented when Amlodipine is combined with other antihypertensive agents, Sildenafil, or Alcohol.

Timing and Population Notes

A timing-based administration rule is documented for certain fixed-dose combinations: the Amlodipine-containing product must be administered at least 4 hours before Colesevelam hydrochloride to manage reduced exposure of the co-administered drug. The interaction risk is officially noted as potentially more significant in patients with hepatic impairment, as their reduced clearance leads to a higher systemic exposure of Amlodipine. Furthermore, the consumption of Grapefruit or Grapefruit Juice is officially not recommended due to the potential for increased Amlodipine bioavailability.

Mechanism of Action

How Almacor Works: Mechanism of Action

Almacor's mechanism of action is focused on modulating vascular smooth muscle tone and systemic flow resistance through targeted cellular pathways.


Molecular Blockade of L-Type Calcium Channels

The active molecule selectively engages and blocks the Voltage-dependent L-type Calcium Channels predominantly found on peripheral arterial smooth muscle cells. This binding action, classified as slow-channel blockade, effectively inhibits the influx of extracellular calcium ions ( Ca^2+) needed to trigger muscle contraction. This mechanism of selective modulation demonstrates minimal functional effect on the heart's sinoatrial and atrioventricular conduction.


Systemic Reduction of Vascular Resistance

By preventing the rise of intracellular calcium, the drug disrupts the Myosin Light-Chain Kinase (MLCK) pathway, causing the arterial muscle cells to relax, which leads to peripheral arterial vasodilation . This widening of the resistance vessels results in a reduction of the Peripheral Vascular Resistance (PVR). The physiological result is a decrease in the mechanical load (afterload) the heart must overcome.

Dosage and Administration Information

How Almacor is Used: Administration Guidelines

Almacor (Amlodipine) is a long-acting prescription medication. The information below details the standardized procedural rules for administration and dosing, which do not include therapeutic benefits or safety details.

Administration and Dosing

The approved route of administration for Almacor is oral, typically taken as a tablet. Due to its long-acting properties, the medication is generally prescribed for once-daily intake.

Indication Type Standard Starting Oral Dose Maximum Daily Dose
Adult General Dosing 5 mg once daily 10 mg
Pediatric Dosing (6–17 yrs) 2.5 mg once daily 5 mg

Key Usage Instructions

  • Timing: Almacor can be taken with or without food. To maintain consistent drug levels, it should be administered at approximately the same time each day.
  • Duration: The medication is intended for chronic, long-term management.
  • Dose Adjustment (Titration): Dosage changes are typically made gradually, often over a period of 7 to 14 days, allowing for the full response to be assessed before proceeding.

Population-Specific Dosing

Certain patient populations may require a lower initial dosage. For older adults and patients with hepatic (liver) impairment, a lower starting dose of 2.5 mg once daily is common, with titration proceeding slowly. For patients with renal impairment, the usual initial dose is generally applied.

Recent Clinical Evidence

Almacor: Recent Clinical Evidence


Evidence for Use in Sustained High Blood Pressure (Hypertension)

The clinical evaluation for Almacor in high blood pressure primarily involves Randomized Controlled Trials (RCTs) and various other trial types. These studies were structured to examine the use of Almacor in various adult populations including those with other conditions like diabetes. Additionally, large-scale trials evaluating long-term measurements were conducted, some lasting several years.

Research examined two main areas of measurement: short-term physiological changes and long-term cardiovascular measurements. The longer-duration trials tracked the occurrence of major events, such as hospitalizations related to stroke or myocardial infarction, to examine how patterns evolved over the study duration in the observed populations. These findings describe patterns observed in the studies, which add to the evidence base for hypertension research.

Evidence for Use in Chronic Chest Pain (Angina)

Research concerning Almacor's role in chronic chest pain, or angina, includes placebo-controlled trials that have been studied for its use in two distinct types: chronic stable angina and vasospastic angina (Prinzmetal’s). These studies focused on measurements related to physical discomfort and daily functioning.

For chronic stable angina, research explored measurements such as a patient's exercise tolerance time and the frequency of episodic changes in chest pain experienced per week. For the less common vasospastic angina, studies specifically monitored physiological strain related to coronary artery spasm. Research examining long-term research related to mortality in all patient sub-groups remains less characterized than the evidence related to symptom control. Available sample sizes were modest for vasospastic angina, and the evidence quality varies across studies.


Evidence Gaps and Research Uncertainties

As with any medication, the research evidence for Almacor has specific limitations and gaps. Evidence quality varies across studies, and the results apply only to the populations studied. A primary area of limited data is in the pediatric population below the age of six. Additionally, while a substantial body of data on long-term measurements exists for high blood pressure, research into long-term measurements related to functional measures in all angina patient sub-groups is not fully established.

Frequently Asked Questions (FAQ)

Common questions about Almacor (FAQ)


Q: What happens if someone misses a dose of Almacor?

Regulatory information typically advises that if a dose is forgotten, the person may take it as soon as they remember on that same day. However, if an entire day has passed, it is generally advised to skip the forgotten dose and take the next dose at the usual time the following day. Official instructions caution against taking a double dose to compensate for a missed dose.


Q: Is it common to feel very tired when first starting Almacor?

Yes, common side effects such as fatigue, dizziness, and headache are frequently reported in regulatory documents as occurring at the beginning of treatment. These effects usually improve or lessen as the body adjusts to the medication over time.


Q: Does Almacor interact with common pain relievers like Tylenol or Advil?

Official drug safety materials generally do not list a severe drug-drug interaction with common pain relievers like paracetamol (Tylenol) or ibuprofen (Advil). However, some evidence indicates that ibuprofen and similar non-steroidal anti-inflammatory drugs (NSAIDs) may slightly reduce the blood pressure-lowering effects of Almacor. Any questions about specific pain reliever use are best addressed by a healthcare provider.


Q: Is it necessary to avoid alcohol completely while taking Almacor?

Official documents note that consuming alcohol may lead to an additive blood pressure lowering effect. This can increase the risk of dizziness, light-headedness, or fainting. Discussions about appropriate limits on alcohol consumption while using this medication are best handled by a healthcare provider.


Q: How long does it typically take before Almacor starts to have an effect?

Almacor is a long-acting medication that begins to affect the circulatory system on the day it is started. However, achieving the full therapeutic effect for blood pressure or angina symptoms may typically take a couple of weeks.


Q: If Almacor doesn't work right away, does that mean it won't work at all?

No. Due to the medication's prolonged action and half-life, a gradual dosage adjustment, or titration, over a period of seven to fourteen days is typically recommended to fully assess the patient’s response. The full effect is often established after a few weeks of consistent use.


Q: What is the difference between Almacor and the generic version?

The active ingredient in Almacor is Amlodipine. The generic version contains the same active ingredient at the same strength and is approved by regulatory bodies to be biologically equivalent to the brand-name product. This means the generic version is expected to have the same clinical effect in the body as the brand-name Almacor.


Q: Does Almacor cause weight gain?

Weight gain is listed as an uncommon side effect in regulatory adverse reaction documents. Weight decrease is also listed as an uncommon side effect. Any significant changes in weight should be discussed with a healthcare provider.


Q: Can Almacor make certain chronic conditions worse?

Official prescribing information advises caution if a patient has certain pre-existing conditions, such as severe heart failure or severe hepatic (liver) impairment. The use of Almacor is strictly prohibited in certain states of cardiovascular instability, including severe low blood pressure or shock. Assessment of an individual's full medical history is a prerequisite for prescribing this medication.


Q: Is there a list of foods or drinks that should be avoided while taking Almacor?

Yes, official safety information states that consumption of grapefruit or grapefruit juice is not recommended because it may increase the drug’s effects in the body. Caution is also advised regarding alcohol consumption due to the potential for lowering blood pressure too much.


Q: How frequently are patients required to get blood work done while on Almacor?

Regulatory information generally advises that blood or urine tests may be needed to check progress and monitor for any unwanted effects during treatment. This closer monitoring is particularly noted for patients with pre-existing severe hepatic (liver) impairment.


Q: Can women who are planning to become pregnant use Almacor?

Regulatory guidance states that the drug is restricted during pregnancy and permitted only when the potential benefit is judged to outweigh the potential risk to the fetus. Women of child-bearing potential often use contraception when taking this type of medication, and any questions regarding use while planning pregnancy are clinical matters for a healthcare provider.


Q: Is it normal to feel anxious after starting Almacor?

Anxiety is listed as an uncommon side effect in the postmarketing experience section of regulatory documents. Any feelings of anxiety that occur should be discussed with a healthcare professional.


Q: Are there any specific dietary restrictions mentioned in the Almacor prescribing information?

Yes, the prescribing information specifically cautions against consuming grapefruit juice. Almacor may generally be taken with or without food. However, if taken alongside certain other medications (like Colesevelam), specific timing rules for administration must be followed.


Q: Does using Almacor affect the ability to drive or operate machinery?

Official safety documents advise caution with driving or operating machinery. If side effects such as dizziness, tiredness, or headache occur, regulatory guidance advises avoiding driving or operating machinery. This risk is typically higher at the start of treatment or following a dose increase.


Q: What are the risks if Almacor is accidentally taken by a child?

Accidental ingestion or overdose can be dangerous and is considered a medical emergency. Overdose may cause severe low blood pressure (hypotension), dizziness, or fainting in children. It is mandatory to keep this medicine out of the reach and sight of children, as stated in the storage instructions.


Q: Can Almacor cause vision changes?

Vision-related issues are noted as uncommon side effects in regulatory documents. These have included reports of abnormal vision, conjunctivitis, and double vision (diplopia).


Q: Why do some studies use Almacor as a comparator drug?

Almacor is often used as a standard benchmark in studies because it is a well-characterized medication with an established long duration of action. Its prolonged therapeutic half-life and reliable efficacy in once-daily dosing make it a consistent agent for comparison in clinical trials.


Q: Can Almacor be crushed or cut (clarification on usage form)?

Yes, regulatory and consensus guidelines indicate that Almacor tablets can be crushed and mixed with a small amount of soft food, such as yogurt or applesauce, or liquid. Once prepared, the mixture is typically administered immediately without chewing. This method is often used for patients who have difficulty swallowing tablets.


Q: What should a patient do if they experience a rare side effect listed for Almacor?

Official guidance advises that any rare or very rare side effects be reported to a healthcare professional. In the event of a severe or serious side effect, immediate contact with a doctor or nearest hospital department for evaluation is advised.


Q: Are there any long-term health concerns associated with using Almacor for many years?

Almacor is intended for chronic, long-term management and is generally considered to have a favorable long-term safety profile. However, regulatory documents note that in patients with severe heart failure, some long-term studies have described an increased risk of pulmonary oedema compared to a placebo. Continuous monitoring of the patient's condition is typically recommended during long-term use.


Q: Why is the official dosage range for Almacor so wide?

The official dosage range is wide (e.g., 2.5 mg to 10 mg) to allow for individualized treatment. This range accommodates the necessary gradual dosage adjustment, or titration, over 7 to 14 days, and ensures that lower starting doses are available for specific populations, such as elderly patients and those with hepatic (liver) impairment.


Q: Can I take Almacor if I have a history of heart issues?

Use of Almacor is strictly prohibited in cases of severe low blood pressure or cardiogenic shock. Caution is necessary if a patient has certain conditions, including severe heart failure, aortic stenosis, or a recent heart attack. The specific cardiac history of the individual must be assessed by a healthcare provider.


Q: Are there different forms of Almacor available, like a tablet vs. liquid?

Yes, Almacor is available as the standard oral tablet. Additionally, a liquid suspension formulation is available and often used when a patient, such as a child, has difficulty swallowing the solid tablet form.


Q: What does 'Black Box Warning' mean regarding Almacor?

A Black Box Warning is the FDA’s most serious safety alert, used to notify prescribers and patients about potentially severe or life-threatening effects. While single-entity Almacor (Amlodipine) does not typically carry this warning, certain combination products that include Amlodipine may have one, for example, regarding use in pregnancy.


Q: Do research trials show Almacor is effective for all demographic groups?

Regulatory documents state that the results of clinical trials only apply to the specific populations that were studied. While Almacor has been examined in various adult and pediatric groups, data in specific populations, such as pediatric patients below the age of six, is officially noted as limited.


Q: What is the process for discontinuing Almacor?

Discontinuing Almacor is a clinical decision that is typically managed under the direct supervision of a healthcare professional. Official guidance advises against the abrupt cessation of this type of medication, particularly for patients using it to treat angina (chest pain).


Q: Does Almacor affect hormone levels?

Regulatory adverse reaction documents list sexual dysfunction, affecting both males and females, as an uncommon reaction associated with the medication. Furthermore, animal studies have noted potential adverse effects on male fertility.


Q: How quickly does Almacor leave the system after the last dose?

Amlodipine has a prolonged elimination from the body, with a terminal half-life that typically ranges between 30 and 50 hours. This means that the active substance remains in the body for several days after the last dose is taken.


Q: Why do some user reviews mention feeling 'foggy' on Almacor?

The official adverse reaction list includes common side effects such as dizziness, somnolence (sleepiness), and fatigue. These central nervous system and general effects are considered the likely contributors to the patient-reported experience of feeling 'foggy' or mentally unclear.


Q: Are there any alternatives to Almacor that work similarly?

Yes. Almacor is chemically classified as a dihydropyridine calcium channel blocker (CCB). Other similar medicines in this specific class, such as nifedipine or felodipine, are available, as are other classes of drugs used to treat high blood pressure.

How should Almacor be stored and disposed of?

The storage and disposal of Almacor (Amlodipine) must strictly follow official regulatory instructions to ensure product quality and safety.

Storage Conditions

  • Temperature: Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), with temporary excursions permitted up to 30 C [2.2]. The tablets must be kept from freezing [2.2].
  • Protection: The product must be protected from light, excess heat, and moisture [2.2]. Store in the container it came in, ensuring it is tightly closed [2.2].
  • Child Safety: It is mandatory to keep this medicine out of the reach and sight of children [2.2].

Disposal Instructions

Outdated or unused medicine must be disposed of as directed by a healthcare professional or through a local take-back program [2.7]. Regulatory documentation states that the product should not be flushed down the toilet or disposed of into the sanitary sewer system [2.3, 2.6]. Disposal must comply with all local, regional, and national requirements for pharmaceutical waste [1.5].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Almacor found in:

A-Z Index: